New research developments increase therapeutic options for thyroid cancer and bone pain palliation.
Williams
J E
JE
D018712:Analgesics, Non-Narcotic / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000532:radiotherapy* / Q000556:secondary*; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D007554:Isotopes; D008297:Male; D009942:Organometallic Compounds / Q000627:therapeutic use; D009943:Organophosphorus Compounds / Q000627:therapeutic use; D010166:Palliative Care; D004369:Pentetic Acid / Q000627:therapeutic use; D011868:Radioisotopes / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D012493:Samarium / Q000627:therapeutic use; D013324:Strontium / Q000627:therapeutic use; D013326:Strontium Radioisotopes / Q000627:therapeutic use; D013964:Thyroid Neoplasms / Q000473:pathology / Q000628:therapy*; D013972:Thyrotropin / Q000627:therapeutic use; D014001:Tin / Q000627:therapeutic use
D018712:Analgesics, Non-Narcotic; D007457:Iodine Radioisotopes; D007554:Isotopes; D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; D011868:Radioisotopes; D011994:Recombinant Proteins; D013326:Strontium Radioisotopes; D012493:Samarium; D014001:Tin; C061972:samarium Sm-153 lexidronam; D004369:Pentetic Acid; D013972:Thyrotropin; C025700:strontium chloride; D013324:Strontium